This study will evaluate the role of mass-based response testing (MRT) to select and deliver personalized hyperthermic intraperitoneal chemotherapy (HIPEC) regimens to patients with peritoneal metastasis (PM) from high-grade appendiceal adenocarcinomas (HGAA) and colorectal cancer (CRC).
Has histologically confirmed peritoneal metastases with primary diagnosis of AJCC 8th Edition Stage IV
Appendiceal adenocarcinoma (moderately/poorly differentiated, and/or signet ring cell tumors)
Colorectal adenocarcinoma
Suspected colon, small bowel, or appendiceal adenocarcinoma in setting of unknown primary
Has a positive urine pregnancy test within 3 days prior to randomization or treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Has a known allergy to medications used in this study. Note: In the event that 3 days have elapsed between the screening pregnancy test and the first dose of study intervention, another pregnancy test (urine or serum) must be performed and must be negative for the participant to start receiving study medication.
Has hypoxia as defined by pulse oximeter reading <92% at rest or requires intermittent or chronic supplemental oxygen.
No concurrent malignancy that may interfere with the study aims at the discretion of the investigator.
Yale University
Lead sponsor
Travera Inc
Collaborator